A review exploring the translational perspective of artificial intelligence in drug discovery and formulation development
Annales Pharmaceutiques Françaises · 2026-06 · 84 (4) · 559-594
DOI: 10.1016/j.pharma.2026.01.007 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annales Pharmaceutiques Françaises, 2026-06. Verfasst von Babita Agarwal und 5 weiteren Autor:innen. Beteiligte Einrichtung: Marathwada Mitra Mandal's College of Pharmacy, Thergaon (Kalewadi), Pune, Maharashtra 411033, India. Hauptthemen laut MEDLINE: Artificial Intelligence, Drug Discovery, Drug Development. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 270 Literaturangaben.
Abstract (Originalsprache)
The drug development pipeline remains extraordinarily complex, costly, and time-intensive, typically requiring 10-15years and $2-3 billion per approved drug. This review presents a translational perspective on how artificial intelligence (AI) and machine learning (ML) are renovating pharmaceutical R&D across the entire value chain while maintaining rigorous safety and efficacy standards. In drug discovery, deep learning platforms enable virtual screening of billion-compounds, reducing target identification from years to months while improving hit rates by 30-50%. Preclinical development benefits from AI-powered toxicity prediction, potentially eliminating 40% of animal testing through accurate in silico models. Clinical trials are optimized through digital twin technology, reducing patient cohorts by 25-30% without compromising statistical power. Post-marketing surveillance is accelerated 100-fold through AI-driven real-world evidence analysis. Across the development lifecycle, AI delivers 30-60% time savings and 25-40% cost reductions while increasing success rates through enhanced predictive capabilities. Formulation development benefits from ML algorithms that optimize drug compositions and stability, reducing trial-and-error experimentation. However, challenges persist in data quality, algorithmic bias, and regulatory acceptance of AI-derived evidence. This review provides a balanced perspective on AI's transformative potential in drug discovery and various formulation developments, along with its limitations, offering a roadmap for successful implementation in pharmaceutical R&D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Marathwada Mitra Mandal's College of Pharmacy, Thergaon (Kalewadi), Pune, Maharashtra 411033, India.
- Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
- KLE College of Pharmacy (A constituent of KLE Academy of Higher Education and Research, Belagavi), Rajajinagar, Bengaluru 560010, India.
- Marathwada Mitra Mandal's College of Pharmacy, Thergaon (Kalewadi), Pune, Maharashtra 411033, India. Electronic address: sachin10pharmacy@gmail.com.
Zitieren
APA
Agarwal, B., Gaware, S., More, N., Shinde, R., Shivakumar, H. N., & Jagdale, S. (2026). A review exploring the translational perspective of artificial intelligence in drug discovery and formulation development. Annales Pharmaceutiques Françaises, 84(4), 559-594. https://doi.org/10.1016/j.pharma.2026.01.007
Vancouver
Agarwal B, Gaware S, More N, Shinde R, Shivakumar HN, Jagdale S. A review exploring the translational perspective of artificial intelligence in drug discovery and formulation development. Annales Pharmaceutiques Françaises. 2026;84(4):559-594. doi:10.1016/j.pharma.2026.01.007
BibTeX
@article{Agarwal2026,
author = {Agarwal, Babita and Gaware, Saurabh and More, Namdev and Shinde, Rushikesh and Shivakumar, Hagalavadi Nanjappa and Jagdale, Sachin},
title = {A review exploring the translational perspective of artificial intelligence in drug discovery and formulation development},
journal = {Annales Pharmaceutiques Françaises},
year = {2026},
volume = {84},
number = {4},
pages = {559--594},
doi = {10.1016/j.pharma.2026.01.007}
}
EUVIMED